Effects of S-methylmethionine (vitamin U) on experimental nephrotic hyperlipidemia.
The effects of S-methylmethionine sulfonium chloride (MMSC, vitamin U) on aminonucleoside-induced nephrotic hyperlipidemia in rats were investigated. We found that repeated oral administration of MMSC (dose: daily 1000 mg/kg) exhibited significant amelioration of plasma chloresterol and phospholipids levels. Also, the treatment improved nephrotic syndrome itself by producing an increase of urinary volume and a decrease of urinary protein excretion. The results suggest that MMSC may be useful as single or combined therapy for human nephrotic syndrome and its related hyperlipidemia as a safety drug.
D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D004327:Drinking Behavior / Q000187:drug effects; D005247:Feeding Behavior / Q000187:drug effects; D006949:Hyperlipidemias / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D009401:Nephrosis / Q000139:chemically induced / Q000188:drug therapy*; D009929:Organ Size / Q000187:drug effects; D010743:Phospholipids / Q000097:blood; D011684:Purine Nucleosides / Q000494:pharmacology; D051381:Rats; D014814:Vitamin U / Q000627:therapeutic use*; D014815:Vitamins / Q000627:therapeutic use*
D010743:Phospholipids; D011684:Purine Nucleosides; D014815:Vitamins; D014814:Vitamin U; D002784:Cholesterol